Findings

What do systematic reviews say?

4,776 questions · 7,311 findings · 959 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1,498 · 20.5%GRADE not reported 303 · 4.1%Very low 1,839 · 25.2%Low 1,991 · 27.2%Moderate 1,277 · 17.5%High 403 · 5.5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Low vs high 17ß‐oestradiol dose

Adverse events · young women with Turner syndrome who have completed pubertal induction

1 finding from 1 review

Hormone therapy for uterine and endometrial development in women with premature ovarian insufficiency 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 20 participants
Very low

Low vs high 17ß‐oestradiol dose

Uterine volume (cm³) · young women with Turner syndrome who have completed pubertal induction

2 findings from 1 review

Hormone therapy for uterine and endometrial development in women with premature ovarian insufficiency 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 20 participants
Very low
Hormone therapy for uterine and endometrial development in women with premature ovarian insufficiency 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 20 participants
Very low

Low vs high 17ß‐oestradiol dose

Endometrial thickness (mm) · young women with Turner syndrome who have completed pubertal induction

The review found no eligible studies for this question.

1 finding from 1 review

Hormone therapy for uterine and endometrial development in women with premature ovarian insufficiency 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Comparison 3. Interactive educational meetings vs didactic (lecture‐based) educational meetings

Improvement in patients' low‐density lipoprotein cholesterol (median and meanf)Â · health personnel

1 finding from 1 review

Continuing education meetings and workshops: effects on professional practice and healthcare outcomes 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 54 participants
Very low

Prostagladin/prostacyclin analogues vs placebo

Migraine frequency Number of attacks · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 118 participants
Low

Slow vs fast subcutaneous heparin injection

Adverse effects: pain on injection (solution deposition), Heft-Parker VAS 0-170 mm · patients treated with subcutaneous heparin injections

1 finding from 1 review

Slow versus fast subcutaneous heparin injections for prevention of bruising and site pain intensity 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 140 participants
Low

Slow vs fast subcutaneous heparin injection

Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · patients treated with subcutaneous heparin injections

1 finding from 1 review

Slow versus fast subcutaneous heparin injections for prevention of bruising and site pain intensity 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 103 participants
Low

Slow vs fast subcutaneous heparin injection

Bruise size 48 hours after injection (mm/mm2) · patients treated with subcutaneous heparin injections

1 finding from 1 review

Slow versus fast subcutaneous heparin injections for prevention of bruising and site pain intensity 2021 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 503 participants
Very low

Slow vs fast subcutaneous heparin injection

Bruise size ‐ 60 hours after injection (mm2) · patients treated with subcutaneous heparin injections

1 finding from 1 review

Slow versus fast subcutaneous heparin injections for prevention of bruising and site pain intensity 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 84 participants
Low

Slow vs fast subcutaneous heparin injection

Bruise size ‐ 72 hours after injection (mm2) · patients treated with subcutaneous heparin injections

1 finding from 1 review

Slow versus fast subcutaneous heparin injections for prevention of bruising and site pain intensity 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 140 participants
Low

Slow vs fast subcutaneous heparin injection

Bruise incidence ‐ 48 hours after injection · patients treated with subcutaneous heparin injections

Slow may leads to lower bruise incidence ‐ 48 hours after injection compared with fast subcutaneous heparin injection (low certainty).

2 findings from 1 review

Slow versus fast subcutaneous heparin injections for prevention of bruising and site pain intensity 2021 · Cochrane Headline outcomes only
OR 0.39 [0.26, 0.6]
3 studies · 444 participants
Low
Slow versus fast subcutaneous heparin injections for prevention of bruising and site pain intensity 2021 · Cochrane Headline outcomes only
OR 0.25 [0.1, 0.65]
2 studies · 84 participants
Low

Propyl betaine and polihexanide vs Normal saline

Procedural pain · participants with chronic leg ulcers

1 finding from 1 review

Wound cleansing for treating venous leg ulcers 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 38 participants
Very low

Mobile phone interventions vs usual care

Objective measure of medication adherence: Cholesterol (low‐density lipoprotein) · people prescribed medication for primary prevention of cardiovascular disease

1 finding from 1 review

Mobile phone‐based interventions for improving adherence to medication prescribed for the primary prevention of… 2021 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 5441 participants
Low

Pneumococcal conjugate vaccine vs control vaccine

CRM197‐PCV7in low‐risk infants · infants (predominantly < 6 months of age) and older children (aged 1 to 7 years)

1 finding from 1 review

Pneumococcal conjugate vaccines for preventing acute otitis media in children 2020 · Cochrane Headline outcomes only
6
2 studies · 39530 participants
Moderate

Pneumococcal conjugate vaccine vs control vaccine

OMPC‐PCV7in low‐risk infants · infants (predominantly < 6 months of age) and older children (aged 1 to 7 years)

1 finding from 1 review

Pneumococcal conjugate vaccines for preventing acute otitis media in children 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1666 participants
Low

Pneumococcal conjugate vaccine vs control vaccine

PHiD‐CV10in low‐risk infants · infants (predominantly < 6 months of age) and older children (aged 1 to 7 years)

1 finding from 1 review

Pneumococcal conjugate vaccines for preventing acute otitis media in children 2020 · Cochrane Headline outcomes only
6
2 studies · 12454 participants
Low

Pneumococcal conjugate vaccine vs control vaccine

PHiD‐CV11in low‐risk infants · infants (predominantly < 6 months of age) and older children (aged 1 to 7 years)

1 finding from 1 review

Pneumococcal conjugate vaccines for preventing acute otitis media in children 2020 · Cochrane Headline outcomes only
34
1 study · 4968 participants
Moderate

Pneumococcal conjugate vaccine vs control vaccine

CRM197‐PCV7in low‐risk infants OMPC‐PCV7in low‐risk infants PHiD‐PC10 and PHiD‐PC11 in low‐risk infants CRM197‐PCV7/9 and CRM197‐PCV7 plus TIVin older children · infants (predominantly < 6 months of age) and older children (aged 1 to 7 years)

1 finding from 1 review

Pneumococcal conjugate vaccines for preventing acute otitis media in children 2020 · Cochrane Headline outcomes only
no estimate extracted
9 studies · 77389 participants
High

Oscillating devices vs different oscillating devices

Sputum: weight (dry or wet) (g) · adults and children with cystic fibrosis

1 finding from 1 review

Oscillating devices for airway clearance in people with cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
Low

Carboplatin vs cisplatin chemotherapy

Overall survival (baseline risks for low‐ and high‐risk groups in the control arm were estimated at 1 year) · combination with third‐generation drugs for advanced non‐small cell lung cancer

Carboplatin showed no clear difference in overall survival (baseline risks for low‐ and high‐risk groups in… compared with cisplatin chemotherapy (high certainty).

1 finding from 1 review

Cisplatin versus carboplatin in combination with third‐generation drugs for advanced non‐small cell lung cancer 2020 · Cochrane Headline outcomes only
HR 0.99 [0.82, 1.2]
10 studies · 2515 participants
High